| Drug General Information |
| Drug ID |
D03AHJ
|
| Former ID |
DNC003124
|
| Drug Name |
Elaidoylamide
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C18H35NO
|
| Canonical SMILES |
CCCCCCCCC=CCCCCCCCC(=O)N
|
| InChI |
1S/C18H35NO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h9-10H,2-8,11-17H2,1H3,(H2,19,20)/b10-9-
|
| InChIKey |
FATBGEAMYMYZAF-KTKRTIGZSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
87668, 585266, 7887303, 10517713, 11038950, 11113753, 14848775, 26751932, 26751933, 26751934, 39316798, 47959446, 48334200, 48417534, 48420782, 49703514, 49846842, 49998733, 50104610, 53788812, 56365478, 57298450, 57358917, 57391339, 76732824, 87350517, 87574113, 91746390, 92309905, 93374599, 98458014, 99300819, 99302337, 103178862, 104046474, 113859930, 124886950, 126524367, 126688203, 134975607, 135626138, 135651530, 137019767, 142454778, 144207642, 144226852, 162174807, 162227355, 163414984, 163849314
|
| Target and Pathway |
| Target(s) |
Phospholipase A2, membrane associated |
Target Info |
Inhibitor |
[1]
|
|---|
|
BioCyc Pathway
|
Phospholipases
|
|
KEGG Pathway
|
Glycerophospholipid metabolism
|
|
Ether lipid metabolism
|
|
Arachidonic acid metabolism
|
|
Linoleic acid metabolism
|
|
alpha-Linolenic acid metabolism
|
|
Metabolic pathways
|
|
Ras signaling pathway
|
|
Vascular smooth muscle contraction
|
|
Pancreatic secretion
|
|
Fat digestion and absorption
|
|
Pathway Interaction Database
|
Glypican 1 network
|
|
Reactome
|
Acyl chain remodelling of PC
|
|
Acyl chain remodelling of PE
|
|
Acyl chain remodelling of PI
|
|
WikiPathways
|
Cardiac Hypertrophic Response
|
|
Glycerophospholipid biosynthesis
|
|
Glycerophospholipid Biosynthetic Pathway
|
|
Spinal Cord Injury
|
|
Eicosanoid Synthesis
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
| References |
| REF 1 | How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. |
|---|
